Summary
For Year 2026-27, Cohance Lifesciences reports the following shareholding: Total Promoters at 57.49%, Mutual Fund at 18.57%, Insurance at 3.13%, Foreign Institutional Investors at 5.59%, Domestic Institutional Investors at 0.1%, and Retail at 15.12%. This breakdown provides a quick snapshot of ownership distribution for Cohance Lifesciences in 2026-27.
Cohance Lifesciences FAQs
As of 05-2026, the promoter shareholding in Cohance Lifesciences stands at 57.49% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Cohance Lifesciences is 5.59% and 0.1% respectively.
The retail shareholding of the Cohance Lifesciences is 15.12%.
Changes in shareholding patterns of Cohance Lifesciences can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Cohance Lifesciences are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Cohance Lifesciences Associated Pages
